

ANTIGENICS INC /DE/  
Form 8-K  
February 21, 2008  
**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15 (d) of**  
**the Securities Exchange Act of 1934**

February 21, 2008  
Date of Report (Date of earliest event reported)

**ANTIGENICS INC.**  
(Exact name of registrant as specified in its charter)

**DELAWARE**                      **000-29089**      **06-1562417**  
(State or other jurisdiction    (Commission    (IRS Employer  
of incorporation)              File Number)    Identification No.)

**162 Fifth Avenue, Suite 900**

**New York, NY**    **10010**  
(Address of Principal Executive Offices)              (Zip  
Code)

**212-994-8200**  
(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 2.02 Results of Operations and Financial Condition**

On February 21, 2008, Antigenics Inc. announced its financial results for the fourth quarter and year ended December 31, 2007. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated February 21, 2008

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANTIGENICS INC.**

Date: February 21, 2008 By: /s/ Garo H. Armen

Garo H. Armen, Ph.D.

Chairman and Chief Executive Officer

---

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press Release dated February 21, 2008